Chemed Corporation (NYSE: CHE) is a Cincinnati, Ohio-headquartered two-business holding company that owns and operates two leading US service businesses: VITAS Healthcare (the largest for-profit hospice provider in the United States) and Roto-Rooter (the largest plumbing, drain-cleaning and water-restoration provider). The corporate history traces back to a 1970s diversified conglomerate (Chemed was at one point part of W.R. Grace, then an independent specialty-chemicals company, then divested its chemicals businesses to focus on the two services franchises); Chemed acquired Roto-Rooter (originally founded 1935) over decades, and acquired the hospice operator that became VITAS (founded 1978 as one of the original US hospice providers) and built it through bolt-ons. The company is run with a deliberately decentralized, low-corporate-overhead style — the two operating businesses operate largely independently with their own management teams, and corporate Chemed focuses on capital allocation, governance and consolidated reporting. Longtime President & CEO Kevin J. McNamara has run Chemed for a multi-decade tenure. The two businesses are very different — VITAS is healthcare-services (Medicare-reimbursed, regulated, labor-intensive) and Roto-Rooter is consumer/commercial trade services (cyclical, weather-sensitive, demand-driven) — but they share defensive characteristics, strong FCF conversion, and dominant US market positions. Geography is overwhelmingly US. The capital structure is conservative — modest debt, often net-cash, no large M&A swings, with cash flow directed at dividends + heavy buybacks + selective bolt-ons. CHE enters FY2026 with FY2025 revenue selected various aggregate ~$2.35-2.65B (~mid-single-digit % growth), aggregate adjusted EPS ~$22-26 and adjusted EBITDA ~$390-450M (~16-18% margin). The first thesis pillar is VITAS Healthcare — the larger and higher-quality of the two businesses (~half-plus of revenue, higher-margin than Roto-Rooter): the business delivers hospice care — interdisciplinary palliative care for terminally ill patients with a prognosis of six months or less — through a clinical team (nurses, physicians, social workers, chaplains, hospice aides, volunteers) that visits patients in homes, nursing facilities, assisted-living, hospitals or VITAS inpatient units; VITAS operates in ~14 states (CA, FL, TX, IL, PA, NJ — dense-population states) with ~18-22 thousand patients/day average daily census; revenue ~90%+ from Medicare hospice fee-for-service per-diem (varying by level of care — routine home care the bulk, plus continuous home care, GIP, respite — updated annually by CMS via the Medicare hospice payment update, typically low-single-digit %); the hospice cap is a key compliance metric (Medicare imposes a per-beneficiary aggregate-payment cap; exceeding requires a refund — VITAS manages census mix and length of stay to stay within); the competitive landscape: VITAS the largest for-profit, competing with Amedisys (AMED, pending UnitedHealth merger), Encompass Health (EHC), Addus HomeCare (ADUS), Aveanna (AVAH), UnitedHealth's (UNH) Optum/LHC, plus not-for-profits and a fragmented small/regional landscape; FY2025 dynamics are admissions and average daily census growing (post-pandemic recovery + aging-population demographics + late-stage cancer/dementia/COPD admissions), length-of-stay watched, nursing-labor cost/availability pressures, revenue growing mid-single-digit, margin holding/expanding modestly; FY2026 catalyst is admissions and census growth, the Medicare payment update, the hospice cap, nursing-labor dynamics, mix shifts, and selective tuck-in M&A; risks/competitors are Medicare reimbursement changes (rates, the cap, regulatory scrutiny, audits — hospice has had episodic government attention with periodic enforcement actions and false-claims cases industry-wide), nursing-labor shortages, length-of-stay/census volatility, and the broader for-profit-hospice competitive set. The second pillar is Roto-Rooter — the smaller, more cyclical, but franchise-strong business (~the remaining portion of revenue): Roto-Rooter is the leading US brand in plumbing services, drain-cleaning, sewer-cleaning and water-restoration — services to residential and commercial customers 24/7, dispatched by call or online booking, with technicians in branded service vehicles; the model combines company-owned branches (the bulk of Chemed's Roto-Rooter revenue) with a franchise network (royalties — the smaller, high-margin piece); services span drain cleaning (the original 1935 product), plumbing repairs (leaks, fixtures, water heaters, sewer lines), water-damage restoration (drying, dehumidification, water extraction, mold remediation — winter freezes, heavy rain/flooding, hurricane events drive demand spikes), and sewer/septic; the brand is extraordinarily strong ('Roto-Rooter' is generic in many consumer minds for drain cleaning), with substantial digital lead-generation (SEO, paid search, Yelp, online booking, branded apps) plus branded fleet vehicles; FY2025 dynamics are residential plumbing mixed (housing-turnover-sensitive softer, water-restoration steady-to-strong on weather, drain-cleaning steady), pricing modestly higher, technician labor a watch item, digital lead-acquisition costs rising; FY2026 catalyst is residential plumbing demand, water-restoration call volumes (weather-event driven), pricing/mix, technician availability and productivity, digital lead generation, and any franchise/branch acquisition; risks/competitors are housing-turnover cyclicality (recessions reduce discretionary repairs), weather-event variability, intense local competition from ARS/Rescue Rooter, Mr. Rooter (Neighborly), Benjamin Franklin Plumbing, local plumbing contractors, HVAC-and-plumbing private-equity roll-ups (Frontier Service Partners, Comfort Systems USA (FIX) on the larger commercial side, ServiceMaster's home-services brands), technician-labor inflation, and digital lead-cost inflation. The capital story: a growing dividend (~$1.80-2.05/share annually, ~0.3-0.5% yield — modest yield by design, with focus on growth; many consecutive years of raises), heavy share buybacks (~14-16M diluted shares — a small float — fallen meaningfully over decades through a multi-billion-cumulative repurchase program), net debt ~$0-300M (often net-cash between deals/buyback batches, well below 1x net debt/EBITDA, often net cash), investment-grade or IG-equivalent credit, capital allocation working capital/capex (modest — service businesses) → grow dividend → aggressive buybacks → selective bolt-on M&A (hospice agencies for VITAS, plumbing/water-restoration tuck-ins for Roto-Rooter) → near-net-cash balance, with the steady FCF generation, buyback pace vs cash balance, bolt-on M&A pricing discipline, and the long capital-return track record supporting a premium services-sector multiple as the principal considerations. At ~$450-650 per share on ~14-16M shares (~$7-10B equity, EV broadly similar given near-net-cash) CHE trades at roughly ~20-28x P/E, ~16-22x EV/EBITDA and ~22-30x EV/FCF with a ~0.3-0.5% dividend yield — a premium-services multiple rewarding defensive end-markets, dominant market positions, strong FCF conversion, conservative balance sheet, and multi-decade compounding via buybacks — versus mixed comps: hospice/home-health Amedisys (AMED, pending UnitedHealth), Encompass Health (EHC), Addus HomeCare (ADUS), Aveanna Healthcare (AVAH), UnitedHealth's (UNH) Optum/LHC; plumbing/services Comfort Systems USA (FIX), API Group (APG), Rollins (ROL, branded-services consumer comp), Cintas (CTAS); diversified services compounders Roper (ROP), Heico (HEI). FY2026 base case: ~$2.5-2.8B revenue + ~$23-28 adj. EPS + ~$410-470M adjusted EBITDA + VITAS census growing + Roto-Rooter steady + growing dividend + aggressive buybacks + bolt-on M&A — solid compounding; bull case: ~$2.6-2.95B+ revenue + ~$26-32+ adj. EPS on a stronger VITAS census ramp (favorable demographics + admission improvements + hospice cap managed well), a favorable Medicare payment update, Roto-Rooter benefiting from a busy weather year (water-restoration surge) and housing-turnover recovery, accretive bolt-on M&A, continued buybacks, and a re-rating; bear case: ~$2.2-2.4B revenue + ~$19-23 adj. EPS on a Medicare reimbursement/regulatory headwind (hospice cap tightening, payment-update freeze, audit-driven episode), nursing-labor inflation outrunning pricing, Roto-Rooter softness (quiet weather year, housing/recession drag), competitive intensity from private-equity-backed plumbing roll-ups, and a de-rating. The thesis depends on the VITAS pipeline (census growth + Medicare payment + hospice cap compliance + nursing-labor management + tuck-in M&A) plus the Roto-Rooter pipeline (residential plumbing demand + weather-driven water-restoration + brand strength + technician productivity + tuck-in M&A) plus the conservative balance sheet plus the heavy buyback program plus the growing dividend plus Kevin McNamara's continued stewardship of the decentralized two-business compounding model.

[CHE] Chemed Thesis 2026: A VITAS Hospice Engine and Roto-Rooter Plumbing Franchise Compound Quietly

Key Takeaways

Chemed Corporation (NYSE: CHE) is expected to close FY2025 with selected various aggregate revenue of roughly $2.35-2.65B (~mid-single-digit % growth) and aggregate adjusted EPS in the area of $22-26, with adjusted EBITDA around ~$390-450M (~16-18% margin), under longtime President & CEO Kevin J. McNamara (a multi-decade Chemed executive who has run the company through several capital-allocation cycles) and Executive Chairman / former-CEO transition leadership.
The first deep-dive — VITAS Healthcare — is the largest US for-profit hospice provider (selected various aggregate ~half-plus of consolidated revenue), delivering end-of-life palliative care to terminally ill Medicare beneficiaries across ~14 states, with revenue principally fee-for-service Medicare hospice (a daily per-diem reimbursement); FY2026 catalyst is admissions growth, average daily census, length of stay, the Medicare hospice payment update, and nursing-labor cost/availability.
The second deep-dive — Roto-Rooter — is the leading US plumbing, drain-cleaning, sewer-cleaning and water-restoration franchise/services business (selected various aggregate ~the remaining portion of consolidated revenue), operating both company-owned branches and a franchise network across North America, with FY2026 catalyst being residential plumbing and drain-cleaning demand, water-restoration call volumes (weather-driven), and digital/SEO-driven lead generation.
Capital position is conservative and highly shareholder-friendly: a growing dividend (selected various aggregate ~$1.80-2.05/share annually, a ~0.3-0.5% yield — modest yield by design, with the focus on growth), heavy share buybacks (the ~~14-16M-diluted-share count has fallen steadily over decades), selected various aggregate net cash to modest net debt (~~$0-300M depending on the buyback pace), low leverage (often net-cash), an investment-grade or near-investment-grade credit profile, and a long dividend-growth history.
FY2026 catalysts: VITAS admissions and average-daily-census growth, the Medicare hospice payment update (typically low-single-digit % annually), the hospice cap (a per-beneficiary aggregate-payment limit — a watched compliance metric), nursing-labor availability and cost, Roto-Rooter residential demand and weather-driven water-restoration call volume, continued share buybacks, modest dividend growth, and selective tuck-in M&A in hospice and/or plumbing services.

Company Background

Chemed Corporation, headquartered in Cincinnati, Ohio, is a two-business holding company that owns and operates two leading US service businesses: VITAS Healthcare (the largest for-profit hospice provider in the United States) and Roto-Rooter (the largest plumbing, drain-cleaning and water-restoration provider). The corporate history traces back to a 1970s diversified conglomerate (Chemed was at one point part of W.R. Grace, then an independent specialty-chemicals company, then divested its chemicals businesses to focus on the two services franchises); Chemed acquired Roto-Rooter (originally founded 1935) over decades, and acquired the hospice operator that became VITAS (founded 1978 as one of the original US hospice providers) and built it through bolt-ons. The company is run with a deliberately decentralized, low-corporate-overhead style — the two operating businesses operate largely independently with their own management teams, and corporate Chemed focuses on capital allocation, governance and consolidated reporting. Longtime President & CEO Kevin J. McNamara has run Chemed for a long stretch (multi-decade tenure with the company). The two businesses are very different — VITAS is healthcare-services (Medicare-reimbursed, regulated, labor-intensive) and Roto-Rooter is consumer/commercial trade services (cyclical, weather-sensitive, demand-driven) — but they share defensive characteristics, strong free-cash-flow conversion, and dominant US market positions in their respective categories. Geography is overwhelmingly US (with selected Roto-Rooter exposure in Canada). The capital structure is conservative — modest debt, often net-cash, no large M&A swings, with cash flow directed at dividends + heavy buybacks + selective bolt-ons. Risks: VITAS Medicare reimbursement (the hospice cap, payment updates, audit/compliance risk), nursing-labor inflation and availability (a structural healthcare-services issue), Roto-Rooter consumer/residential cyclicality (housing demand, weather variability), competitive intensity in plumbing services from local/regional players (often dirt-cheap), and key-man/leadership-transition risk given McNamara's long tenure.

VITAS Healthcare: The Largest US For-Profit Hospice Provider

VITAS Healthcare is the larger and higher-quality of the two Chemed businesses — selected various aggregate ~half-plus of consolidated revenue and a higher-margin profile than Roto-Rooter. The business delivers hospice care — interdisciplinary palliative care for terminally ill patients with a prognosis of six months or less, focused on comfort and quality of life rather than curative treatment — through a clinical team (nurses, physicians, social workers, chaplains, hospice aides, volunteers) that visits patients in their homes, nursing facilities, assisted-living, hospitals or VITAS inpatient units. VITAS operates in selected various aggregate ~14 states (concentrated in California, Florida, Texas, Illinois, Pennsylvania, New Jersey and other dense-population states), with selected various aggregate ~18-22 thousand patients/day average daily census. Revenue is principally Medicare hospice (selected various aggregate ~90%+ of VITAS revenue from Medicare fee-for-service hospice benefit), paid as a per-diem rate that varies by level of care (routine home care being the bulk, with continuous home care, general inpatient care, and respite care at higher per-diem rates) and is updated annually by CMS (the Medicare hospice payment update typically runs low-single-digit % annually). The hospice cap is a key compliance metric — Medicare imposes a per-beneficiary aggregate-payment cap on each provider, calculated annually; exceeding the cap requires VITAS to refund the excess — VITAS manages census mix and length of stay to stay within the cap (an issue that historically constrained growth in certain locations). The competitive landscape: VITAS is the largest US for-profit hospice provider, competing against other for-profits (Amedisys (AMED) — Hospice & Home Health, owned by UnitedHealth pending the merger; Encompass Health (EHC) — large home health/inpatient rehab with hospice; Addus HomeCare (ADUS); Aveanna (AVAH); LHC Group within UnitedHealth), large not-for-profit hospices, and a fragmented landscape of small/regional/non-profit hospices. FY2025 dynamics: admissions and average daily census growing (post-pandemic recovery + aging-population demographics + late-stage cancer / dementia / COPD admissions), length-of-stay trends watched, nursing-labor cost and availability pressures (a structural healthcare-labor headwind), revenue growing mid-single-digit, margin holding/expanding modestly. FY2026 catalyst: admissions and census growth, the Medicare payment update, the hospice cap compliance, nursing-labor dynamics, mix shifts (continuous home care, GIP), and selective tuck-in M&A (bolt-on hospice agencies). Risks/competitors: Medicare reimbursement changes (rates, the cap, regulatory scrutiny, audits — hospice has had episodic government attention over the past two decades on profit margins, with periodic enforcement actions and false-claims cases industry-wide), nursing-labor shortages, length-of-stay/census volatility, and the broader for-profit-hospice competitive set.

Roto-Rooter: Plumbing, Drain-Cleaning, and Water-Restoration Leadership

Roto-Rooter is the smaller, more cyclical, but franchise-strong second Chemed business — selected various aggregate ~the remaining portion of consolidated revenue. Roto-Rooter is the leading US brand in plumbing services, drain-cleaning, sewer-cleaning, and water-restoration — services delivered to residential and commercial customers, available 24/7, dispatched by call or online booking, with technicians driving branded service vehicles. The business model combines company-owned branches (selected various aggregate ~the bulk of Chemed's Roto-Rooter revenue — Roto-Rooter directly operates branches in major US metros, paying its own technicians and pocketing the full economics) with a franchise network (independent franchisees operating the Roto-Rooter brand in smaller markets, paying royalties — selected various aggregate the smaller revenue piece but high-margin). Services span drain cleaning (the original 1935 product — clearing clogged drains with the "Roto-Rooter" machine that gave the company its name), plumbing repairs (leaks, fixtures, water heaters, sewer lines), water-damage restoration (drying, dehumidification, water extraction, mold remediation — particularly demand-spike during winter freezes, heavy rain/flooding, hurricane events), and sewer/septic services. The brand is extraordinarily strong — "Roto-Rooter" is generic in many consumer minds for drain cleaning — and the company benefits from substantial digital lead-generation investment (SEO, paid search, Yelp, online booking, branded apps) plus a fleet of branded vehicles that act as rolling billboards. FY2025 dynamics: residential plumbing demand mixed (housing-turnover-sensitive plumbing repairs softer, water-restoration steady-to-strong on weather events, drain-cleaning steady), pricing modestly higher, technician labor and recruiting a watch item, digital lead acquisition costs rising (paid-search competition). FY2026 catalyst: residential plumbing demand (housing-turnover-sensitive), water-restoration call volumes (weather-event driven), pricing/mix, technician availability and productivity, digital lead generation efficiency, and any franchise/branch acquisition activity. Risks/competitors: housing-turnover and home-investment cyclicality (Roto-Rooter benefits from house-related plumbing issues — recessions reduce discretionary repairs); weather-event variability (hurricane and freeze seasons drive water-restoration spikes — a quiet year hurts); intense local competition from regional plumbing chains (ARS/Rescue Rooter, Mr. Rooter (Neighborly), Benjamin Franklin Plumbing, Roto-Rooter franchisees outside Chemed control), local plumbing contractors, and increasingly HVAC-and-plumbing roll-ups (private equity has been actively rolling up residential plumbing — Frontier Service Partners, Comfort Systems USA (FIX) on the larger commercial side, ServiceMaster's home-services brands); technician-labor inflation; and digital lead-cost inflation as paid-search bidding intensifies.

Capital Position + Balance Sheet

Chemed runs a conservative, shareholder-friendly balance sheet. The company pays a growing dividend (selected various aggregate annual dividend per share in the area of $1.80-2.05, a yield roughly ~0.3-0.5% — a modest yield by design, with the focus on growth, having raised the dividend for many consecutive years), conducts heavy share buybacks (the diluted share count is selected various aggregate ~14-16M — a small float — and has fallen meaningfully over decades through a consistent multi-billion-cumulative repurchase program), and carries selected various aggregate net debt of ~$0-300M — often net-cash between deals/buyback batches — with low leverage (well below 1x net debt/EBITDA, often net cash); the credit profile is investment-grade or investment-grade-equivalent. Capital allocation order: fund the operating businesses' working capital/capex (modest — these are service businesses, not capital-intensive) → grow the dividend → aggressive buybacks → selective bolt-on M&A (hospice agencies for VITAS, plumbing/water-restoration tuck-ins for Roto-Rooter) → maintain a near-net-cash balance sheet. There is no material pension overhang; the principal balance-sheet considerations are the steady FCF generation, the buyback pace (vs cash balance), bolt-on M&A pricing discipline, and the long capital-return track record that supports a premium services-sector multiple.

Key Core Metrics

Revenue: selected various aggregate ~$2.35-2.65B FY2025 (~mid-single-digit % growth)
Adjusted EBITDA: selected various aggregate ~$390-450M FY2025 (~16-18% margin)
Adjusted EPS: selected various aggregate ~$22-26 FY2025
VITAS Healthcare: largest US for-profit hospice; selected various aggregate ~half-plus of revenue
VITAS states: ~14 states (CA, FL, TX, IL, PA, NJ, others — dense-population states)
VITAS census: selected various aggregate ~18-22 thousand patients/day average daily census
VITAS payor mix: ~90%+ Medicare hospice (fee-for-service per-diem)
Medicare hospice payment update: typically low-single-digit % annually (CMS-set)
Hospice cap: per-beneficiary aggregate-payment cap — a managed compliance metric
Nursing labor: a structural cost and availability watch item
Roto-Rooter: leading US plumbing/drain-cleaning/water-restoration franchise + branch network; selected various aggregate ~the remaining portion of revenue
Roto-Rooter mix: company-owned branches (bulk of revenue) + franchise royalties (smaller, high-margin)
Roto-Rooter services: drain cleaning + plumbing repairs + water-damage restoration + sewer/septic
Brand: "Roto-Rooter" is generic in many consumer minds; heavy digital lead generation
Geography: overwhelmingly US (Canada for Roto-Rooter to a small degree)
Net debt: selected various aggregate ~$0-300M FY2025 (often net cash between deals)
Net debt / EBITDA: selected various aggregate well below 1x (often net cash)
Credit profile: investment-grade or investment-grade-equivalent
Dividend: selected various aggregate ~$1.80-2.05/share annually (~0.3-0.5% yield; many consecutive years of raises)
Buybacks: heavy/ongoing; ~14-16M diluted shares (very small float; declining over time)
Capex: modest (service businesses); strong FCF conversion
Capital allocation: working capital → dividend → buybacks → bolt-on M&A → net-cash balance
CEO: Kevin J. McNamara (President & CEO; multi-decade Chemed tenure)

Market Evaluation

At roughly ~$450-650 per share on ~14-16M shares, Chemed carries an equity value of selected various aggregate ~$7-10B (and an enterprise value broadly similar given near-net-cash), which on FY2025 cash flow is roughly ~20-28x P/E, ~16-22x EV/EBITDA and ~22-30x EV/FCF with a ~0.3-0.5% dividend yield — a premium-services multiple, the market rewarding Chemed's defensive end-markets, dominant market positions, strong FCF conversion, conservative balance sheet, and multi-decade track record of consistent compounding through buybacks. The comp set is genuinely a mix: on the hospice/home-health side, Amedisys (AMED, hospice + home health, pending UnitedHealth merger), Encompass Health (EHC, inpatient rehab + hospice), Addus HomeCare (ADUS), Aveanna Healthcare (AVAH), and UnitedHealth's (UNH) home-health franchise (which has Optum/LHC Group); on the plumbing/services side, no large pure-play public comp — read-throughs include Comfort Systems USA (FIX, commercial HVAC/plumbing), API Group (APG, commercial fire/safety/specialty services), Rollins (ROL, pest control — closest "branded-services consumer" comp), Cintas (CTAS); on diversified services compounders, Roper (ROP), Heico (HEI), and the broader compounder/quality-services universe. FY2026 base case: selected various aggregate ~$2.5-2.8B revenue + ~$23-28 adj. EPS + ~$410-470M adjusted EBITDA + VITAS census growing + Roto-Rooter steady + the growing dividend + aggressive buybacks + bolt-on M&A — solid compounding. Bull case: selected various aggregate ~$2.6-2.95B+ revenue + ~$26-32+ adj. EPS on a stronger VITAS census ramp (favorable demographics + admission improvements + the hospice cap managed well), a favorable Medicare payment update, Roto-Rooter benefiting from a busy weather year (water-restoration surge) and a housing-turnover recovery, accretive bolt-on M&A, continued buybacks shrinking the share count, and a multiple expansion. Bear case: selected various aggregate ~$2.2-2.4B revenue + ~$19-23 adj. EPS on a Medicare reimbursement/regulatory headwind (a hospice cap tightening, a payment-update freeze, an audit-driven episode), nursing-labor inflation outrunning pricing, Roto-Rooter softness (a quiet weather year, a housing/recession drag on residential plumbing), competitive intensity from local/private-equity-backed plumbing roll-ups, and a multiple de-rating. The thesis turns on the VITAS pipeline (census growth + Medicare payment + hospice cap compliance + nursing-labor management + tuck-in M&A) plus the Roto-Rooter pipeline (residential plumbing demand + weather-driven water-restoration + brand strength + technician productivity + tuck-in M&A) plus the conservative balance sheet plus the heavy buyback program plus the growing dividend plus Kevin McNamara's continued stewardship of the decentralized two-business compounding model.